129 related articles for article (PubMed ID: 36395883)
1. Diptoindonesin G is a middle domain HSP90 modulator for cancer treatment.
Donahue K; Xie H; Li M; Gao A; Ma M; Wang Y; Tipton R; Semanik N; Primeau T; Li S; Li L; Tang W; Xu W
J Biol Chem; 2022 Dec; 298(12):102700. PubMed ID: 36395883
[TBL] [Abstract][Full Text] [Related]
2. Diptoindonesin G, a new Hsp90 drug.
Wickramaratne A; Wickner S
J Biol Chem; 2023 Jan; 299(1):102826. PubMed ID: 36572186
[TBL] [Abstract][Full Text] [Related]
3. Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer.
Gonzalez TL; Hancock M; Sun S; Gersch CL; Larios JM; David W; Hu J; Hayes DF; Wang S; Rae JM
Breast Cancer Res Treat; 2020 Apr; 180(3):611-622. PubMed ID: 32067153
[TBL] [Abstract][Full Text] [Related]
4. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
5. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
[TBL] [Abstract][Full Text] [Related]
7. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
[TBL] [Abstract][Full Text] [Related]
8. Effects of HIV protease inhibitor ritonavir on Akt-regulated cell proliferation in breast cancer.
Srirangam A; Mitra R; Wang M; Gorski JC; Badve S; Baldridge L; Hamilton J; Kishimoto H; Hawes J; Li L; Orschell CM; Srour EF; Blum JS; Donner D; Sledge GW; Nakshatri H; Potter DA
Clin Cancer Res; 2006 Mar; 12(6):1883-96. PubMed ID: 16551874
[TBL] [Abstract][Full Text] [Related]
9. Hsp90: an emerging target for breast cancer therapy.
Beliakoff J; Whitesell L
Anticancer Drugs; 2004 Aug; 15(7):651-62. PubMed ID: 15269596
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.
Wong C; Chen S
Cancer Res; 2009 Nov; 69(22):8670-7. PubMed ID: 19861537
[TBL] [Abstract][Full Text] [Related]
12. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
[TBL] [Abstract][Full Text] [Related]
13. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.
Lundgren K; Zhang H; Brekken J; Huser N; Powell RE; Timple N; Busch DJ; Neely L; Sensintaffar JL; Yang YC; McKenzie A; Friedman J; Scannevin R; Kamal A; Hong K; Kasibhatla SR; Boehm MF; Burrows FJ
Mol Cancer Ther; 2009 Apr; 8(4):921-9. PubMed ID: 19372565
[TBL] [Abstract][Full Text] [Related]
14. Identification of mixed lineage leukemia 1(MLL1) protein as a coactivator of heat shock factor 1(HSF1) protein in response to heat shock protein 90 (HSP90) inhibition.
Chen Y; Chen J; Yu J; Yang G; Temple E; Harbinski F; Gao H; Wilson C; Pagliarini R; Zhou W
J Biol Chem; 2014 Jul; 289(27):18914-27. PubMed ID: 24831003
[TBL] [Abstract][Full Text] [Related]
15. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
[TBL] [Abstract][Full Text] [Related]
16. X66, a novel N-terminal heat shock protein 90 inhibitor, exerts antitumor effects without induction of heat shock response.
Zhao Z; Zhu J; Quan H; Wang G; Li B; Zhu W; Xie C; Lou L
Oncotarget; 2016 May; 7(20):29648-63. PubMed ID: 27105490
[TBL] [Abstract][Full Text] [Related]
17. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
18. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.
Xu XL; Bao QC; Jia JM; Liu F; Guo XK; Zhang MY; Wei JL; Lu MC; Xu LL; Zhang XJ; You QD; Sun HP
Sci Rep; 2016 Jan; 6():19004. PubMed ID: 26743233
[TBL] [Abstract][Full Text] [Related]
19. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
[TBL] [Abstract][Full Text] [Related]
20. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain.
Dai J; Chen A; Zhu M; Qi X; Tang W; Liu M; Li D; Gu Q; Li J
Biochem Pharmacol; 2019 May; 163():404-415. PubMed ID: 30857829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
